RI-AG03

RI-AG03 is an orally active and a BBB-penetrable Tau aggregation peptide inhibitor. RI-AG03 inhibits Tau aggregation and improves associated neurodegeneration and behavioral phenotypes in both in vivo and in vitro models. RI-AG03 can be used in the study of tauopathies such as Alzheimer's disease[1][2].

12352209

Tau Protein

Neuronal Signaling

Neuroscience-Neurodegeneration

Neurological Disease

O=C(N[C@H](CCCNC(N)=N)C(N[C@H](CCCNC(N)=N)C(N[C@H](CCCNC(N)=N)C(N[C@H](CCCNC(N)=N)C(N[C@H](CCCNC(N)=N)C(N[C@H](CCCNC(N)=N)C(N[C@H](CCCNC(N)=N)C(NCC(N1[C@H](CCC1)C(N[C@H](CCCCN)C(N[C@H](CC2=CC=C(C=C2)O)C(N[C@H](CCCCNC(C)=O)C(N[C@H]([C@H](C)CC)C(N[C@H](CCC(N)=O)C(N[C@H](C(C)C)C(NCC(N[C@H](CCCNC(N)=N)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@@H](CCCNC(N)=N)NC(C)=O

C104H189N49O22

2477.93

[1]Di Natale G, et al. Aβ and Tau Interact with Metal Ions, Lipid Membranes and Peptide-Based Amyloid Inhibitors: Are These Common Features Relevant in Alzheimer's Disease? Molecules. 2022 Aug 9;27 (16) :5066. |[2]Aggidis A, et al. A novel peptide-based tau aggregation inhibitor as a potential therapeutic for Alzheimer's disease and other tauopathies. Alzheimers Dement. 2024 Nov;20 (11) :7788-7804.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P10861/

Peptides

No Development Reported